Literature DB >> 10188966

Rate-dependent blockade of a potassium current in human atrium by the antihistamine loratadine.

W J Crumb1.   

Abstract

The antihistamine loratadine is widely prescribed for the treatment of symptoms associated with allergies. Although generally believed to be free of adverse cardiac effects, there are a number of recent reports suggesting that loratadine use may be associated with arrhythmias, in particular atrial arrhythmias. Nothing is known regarding the potassium channel blocking properties of loratadine in human cardiac cells. Using the whole-cell patch clamp technique, the effects of loratadine on the transient outward K current (Ito), sustained current (Isus), and current measured at -100 mV (IK1 and Ins), the major inward and outward potassium currents present in human atrial myocytes, were examined in order to provide a possible molecular mechanism for the observed atrial arrhythmias reported with loratadine use. Loratadine rate-dependently inhibited Ito at therapeutic concentrations with 10 nM loratadine reducing Ito amplitude at a pacing rate of 2 Hz by 34.9+/-6.0%. In contrast, loratadine had no effect on either Isus or current measured at -100 mV. These results may provide a possible mechanism for the incidences of supraventricular arrhythmias reported with the use of loratadine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10188966      PMCID: PMC1565832          DOI: 10.1038/sj.bjp.0702273

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

1.  Statistical methods for model discrimination. Applications to gating kinetics and permeation of the acetylcholine receptor channel.

Authors:  R Horn
Journal:  Biophys J       Date:  1987-02       Impact factor: 4.033

2.  Cardiotoxic effect with convulsions in terfenadine overdose.

Authors:  A J Davies; V Harindra; A McEwan; R R Ghose
Journal:  BMJ       Date:  1989-02-04

3.  Pharmacokinetics and dose proportionality of loratadine.

Authors:  J Hilbert; E Radwanski; R Weglein; V Luc; G Perentesis; S Symchowicz; N Zampaglione
Journal:  J Clin Pharmacol       Date:  1987-09       Impact factor: 3.126

4.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches.

Authors:  O P Hamill; A Marty; E Neher; B Sakmann; F J Sigworth
Journal:  Pflugers Arch       Date:  1981-08       Impact factor: 3.657

5.  Prolonged Q-T interval following astemizole overdose.

Authors:  R O Bishop; P L Gaudry
Journal:  Arch Emerg Med       Date:  1989-03

6.  Comparative effects of loratadine and terfenadine on cardiac K+ channels.

Authors:  I Ducic; C M Ko; Y Shuba; M Morad
Journal:  J Cardiovasc Pharmacol       Date:  1997-07       Impact factor: 3.105

7.  Contributions of a transient outward current to repolarization in human atrium.

Authors:  E F Shibata; T Drury; H Refsum; V Aldrete; W Giles
Journal:  Am J Physiol       Date:  1989-12

8.  Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents.

Authors:  Z Wang; B Fermini; S Nattel
Journal:  Circ Res       Date:  1993-12       Impact factor: 17.367

9.  Mechanism of the cardiotoxic actions of terfenadine.

Authors:  R L Woosley; Y Chen; J P Freiman; R A Gillis
Journal:  JAMA       Date:  1993 Mar 24-31       Impact factor: 56.272

10.  Torsades de pointes occurring in association with terfenadine use.

Authors:  B P Monahan; C L Ferguson; E S Killeavy; B K Lloyd; J Troy; L R Cantilena
Journal:  JAMA       Date:  1990-12-05       Impact factor: 56.272

View more
  2 in total

1.  The sulphonylurea glibenclamide inhibits voltage dependent potassium currents in human atrial and ventricular myocytes.

Authors:  P Schaffer; B Pelzmann; E Bernhart; P Lang; H Mächler; B Rigler; B Koidl
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

Review 2.  Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Authors:  Larry K Golightly; Leon S Greos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.